Claims for Patent: 5,804,213

Summary for Patent: 5,804,213

Title:	Biologically active aqueous gel wound dressing
Abstract:	The invention provides a prepackaged dressing including dry particulate solids for forming a pourable, water-based natural or synthetic hydrocolloidal polyemeric gel to dress wounds. The gel contains a biologically active constituent. Liquid and dry, solid particulate components are separate and are mixed just before use. One dry constituent is the hydrocolloid which is contained in a compartment of a sealed container separate from moisture. After mixing with water, the dry hydrocolloid does not become fully hydrated immediately. The liquid component (water) provides a fluid consistency initially. At this stage, the admixture is sufficiently fluid in consistency to allow it to be poured or spread into a wound. Following application to the wound, the hydrated hydrocolloidal dispersion begins to solidify to form a solid, self-supporting flexible dressing structure consisting primarily of water, the hydrocolloid, as well as the biologically active constituent, e.g., an antibiotic, disinfectant, growth factor or the like in contact with the tissue of the animal or human patient. A gelling or cross-linking agent can also be used advantageously with some of the hydrocolloids. The resulting dressing becomes molded to the shape of the wound and contains a large quantity of moisture that will maintain the wound in a moist condition.
Inventor(s):	Rolf; David (Minneapolis, MN)
Assignee:	LecTec Corporation (Minnetonka, MN)
Application Number:	07/914,751
Patent Claims:	1. A pre-packaged wound dressing contained in a package for storing and mixing the dressing from which the dressing can be poured as a liquid and set up as a solid elastic body on the surface of a wound, said dressing comprising, about 3%-15% by weight of a natural or synthetic hydrocolloid polymer in dry particulate form contained in a compartment of said pouch, said polymer is a water soluble or water swellable hydrocolloid comprising a member selected from the group consisting of guar gum, locust bean gum, hydroxypropyl guar gum, polyglucomannan gum, cationic guar gum, anionic guar gum, alginate and xanthan gum, about 70%-95% by weight water contained in a second compartment of the package, the amount of said dry polymer relative to the amount of said water being effective to produce a liquid hydrocolloid dispersion of an initial viscosity which can be poured or spread onto a surface after said dry hydrocolloid polymer is mixed with said water and is capable of setting up to form a solid, said pre-packaged wound dressing including a biologically active substance for treating the wound, the water and the polymer being separated by a removable barrier that is a part of the package separating the polymer from the water to prevent communication between the dry hydrocolloid polymer and water for maintaining the hydrocolloid in the dry state, said dry hydrocolloid polymer, the biologically active substance and water being mixed together by rupturing or removing said barrier to form said liquid dispersion for being poured onto a wound or spread onto a wound after the water and polymer are mixed together, and after application to the wound, said dispersion solidifies to form a gel which is an elastic solid resting upon the wound, said elastic solid gel has a lower surface that corresponds to the shape of the wound surface, said elastic solid gel protects the wound, maintains the wound in a moist condition and maintains said biologically active substance in contact with the wound to promote healing or patient comfort. 2. The wound dressing of claim 1 wherein the biologically active substance comprises a coagulant and astringent comprising alum. 3. The wound dressing of claim 1 wherein the biologically active substance comprises an astringent comprising witch hazel. 4. The wound dressing of claim 1 wherein the biologically active substance comprises an antibiotic selected from the group consisting of neomycin sulfate, bacitracin, polymyxin-B sulfate, oxy tetracylcine hydrochloride, and gramacidin. 5. The wound dressing of claim 1 wherein the biologically active substance is selected from the group consisting of povidone iodine ozone, and hydrogen peroxide. 6. The wound dressing of claim 1 wherein the biologically active substance is a proteolytic enzyme selected from the group consisting of collagenase, streptokinase and streptodornase. 7. The wound dressing of claim 1 wherein the biologically active substance is a polyamine or diamine selected from the group consisting of spermadine, putrescine, cadaverine, cystamine, histadine and a synthetic diamine comprising a polyalkyleneoxide diamine. 8. The wound dressing of claim 1 wherein the biologically active substance is a growth factor selected from the group consisting of platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, and transforming growth factor. 9. The wound dressing of claim 1 wherein the biologically active substance comprises an immunostimulator selected from the group consisting of L-arginine, nitric oxide, quadrol, muramyl dipeptide, and other macrophage activating factors. 10. The wound dressing of claim 1 wherein the biologically active substance comprises hyaluronic acid or hyaluronic acid fragment for promoting the healing of pathogenic wounds, stasis ulcers and chronic wounds. 11. The wound dressing of claim 1 wherein the biologically active substance comprises an analgesic or a narcotic. 12. The wound dressing of claim 1 wherein the biologically active substance comprises an anesthetic selected from the group consisting of lidocaine, procaine and epinephrine. 13. The wound dressing of claim 11 wherein the analgesic or narcotic is selected from the group consisting of morphine, heroin and fentanyl for treatment of pain. 14. The wound dressing of claim 1 wherein said liquid dispersion includes an agent for cross-linking said hydrocolloid polymer and said cross-linking agent comprises at least one member selected from the group consisting of galactose, organic titanate, boric acid, borax, mannose, an oligosaccharide containing either or both galactose or mannose, dihydroxy aluminum sodium carbonate, citric acid, and a soluble source of any of the cations of calcium, magnesium and aluminum.

Details for Patent 5,804,213

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2015-09-08